荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行 转仓市值8.96亿港元

Core Viewpoint - Recent stock transfer of Rongchang Biologics (09995) from BNP Paribas to HSBC Hong Kong valued at HKD 896 million, representing 5.29% of the company [1] Group 1: Stock Transfer - On November 26, shareholders of Rongchang Biologics transferred shares from BNP Paribas to HSBC Hong Kong, with a market value of HKD 896 million [1] Group 2: Analyst Report - Jianyin International raised the target price for Rongchang Biologics by 9% from HKD 110 to HKD 120, maintaining an "outperform" investment rating [1] - The revenue forecasts for Rongchang Biologics for 2025, 2026, and 2027 remain unchanged at RMB 2.8 billion, RMB 3.4 billion, and RMB 4.6 billion respectively [1]